Exchange Traded Concepts LLC Lowers Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Exchange Traded Concepts LLC lowered its position in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 10.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,635 shares of the company’s stock after selling 3,831 shares during the period. Exchange Traded Concepts LLC owned about 0.11% of Fulgent Genetics worth $731,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Asset Dedication LLC purchased a new stake in shares of Fulgent Genetics in the second quarter valued at about $33,000. nVerses Capital LLC purchased a new stake in shares of Fulgent Genetics in the second quarter valued at about $43,000. Signaturefd LLC raised its holdings in shares of Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Fulgent Genetics in the second quarter valued at about $63,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Fulgent Genetics in the first quarter valued at about $178,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

NASDAQ FLGT opened at $19.76 on Friday. Fulgent Genetics, Inc. has a 52-week low of $18.91 and a 52-week high of $30.68. The company has a 50-day simple moving average of $21.86 and a 200 day simple moving average of $21.48. The company has a market capitalization of $591.30 million, a PE ratio of -3.55 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business had revenue of $71.03 million during the quarter, compared to the consensus estimate of $69.07 million. During the same quarter last year, the company posted ($0.33) earnings per share. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. As a group, analysts forecast that Fulgent Genetics, Inc. will post -1.46 EPS for the current fiscal year.

Insider Transactions at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of Fulgent Genetics stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the transaction, the chief executive officer now owns 707,275 shares in the company, valued at $16,147,088.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 4,324 shares of company stock worth $98,717 over the last quarter. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.